![](/images/graphics-bg.png)
Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting
Joint Authors
Bharwani, K. D.
Stronks, D. L.
Dik, W. A.
Huygen, F. J. P. M.
Dirckx, M.
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-09-28
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Previously, we showed that serum soluble interleukin-2 receptor (sIL-2R) levels, a marker for T-cell activation, were higher in complex regional pain syndrome (CRPS) patients than in healthy controls, suggesting pathogenic T-cell activation in CRPS.
Additionally, sIL-2R levels discriminated well between CRPS and healthy controls with a high sensitivity (90%) and specificity (89.5%), suggesting a possible role for sIL-2R in the diagnosis of CRPS.
In order to further validate this marker in the diagnostic workup of CRPS, we conducted this prospective cohort study in which we determined sIL-2R levels in patients that were referred to our tertiary referral center with a suspicion of CRPS in a limb, and subsequently compared sIL-2R levels between the patients that were diagnosed with CRPS (CRPS group) and those who were not (no CRPS group).
A group of anonymous blood bank donors were used as a healthy control group.
Furthermore, we explored the relationship between sIL-2R and CRPS disease severity using the CRPS severity score.
Median sIL-2R levels of both the CRPS group (2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and no CRPS group (3654.0 pg/ml; Q3-Q1: 4429.0-2095.5) were significantly higher than that of the control group (1515.0 pg/ml; Q3-Q1: 1880.0-1150.0): CRPS vs.
controls, p<.001; no CRPS vs.
controls, p<0.001.
Serum sIL-2R levels did not differ significantly between the CRPS and no CRPS group.
A statistically significant negative correlation was observed between sIL-2R levels and the CRPS severity score (rs=−0.468, p=0.024).
Our results confirm our previous findings of higher sIL-2R levels in CRPS patients than in healthy controls.
We further showed that serum sIL-2R cannot differentiate between CRPS and other pain conditions of a limb in a tertiary referral setting.
Interestingly, a negative correlation was found between sIL-2R and CRPS disease severity; this finding warrants further research into the relationship between sIL-2R and CRPS disease severity.
American Psychological Association (APA)
Bharwani, K. D.& Dirckx, M.& Stronks, D. L.& Dik, W. A.& Huygen, F. J. P. M.. 2020. Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting. Mediators of Inflammation،Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1191877
Modern Language Association (MLA)
Bharwani, K. D.…[et al.]. Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting. Mediators of Inflammation No. 2020 (2020), pp.1-10.
https://search.emarefa.net/detail/BIM-1191877
American Medical Association (AMA)
Bharwani, K. D.& Dirckx, M.& Stronks, D. L.& Dik, W. A.& Huygen, F. J. P. M.. Serum Soluble Interleukin-2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting. Mediators of Inflammation. 2020. Vol. 2020, no. 2020, pp.1-10.
https://search.emarefa.net/detail/BIM-1191877
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1191877